Expected Moves

Lonza will present its Q3 2026 Qualitative Business Update alongside its Capital Markets Day in Vacaville, CA, evaluating a shift from the $733.50 baseline.

The anticipated closing of the Capsules & Health Ingredients (CHI) sale, driving a move from $810.00.

Lonza reports Full-Year 2026 results, navigating from an assumed $865.00 level.

An evaluation of ongoing FX headwinds and shifting macro funding environments in Q2 2027, measuring risk from $930.00.

Lonza releases half-year 2027 results, pivoting from the $820.00 anchor to assess organic growth against tough year-over-year comps.